drug · protein
patient view →cenegermin
Phase 2updated 2mo agoby Dompe Farmaceutici SpA🔗 ChEMBL
Phase 2community read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for keratitis and eye disease and 1 investigational indication.
targets
Neurotrophic tyrosine kinase receptor
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that